Elevada presencia de enterobacterias con genes de resistencia antimicrobiana en pacientes diagnosticados de COVID-19 en hospitales públicos del Perú
Author(s)
Carla Liñan-Martínez
Alexander Fajardo-Loyola
Rafael Remon-Chinchay
Diana Romero-Japay
Antonella Bazán-Huapaya
Mercedes Márquez-Espinoza
Mario Chambi-Quispe
Álvaro Luque-Arapa
Jimena Edith Pino-Dueñas
Pilar Elizabeth Diaz-Rengifo
Heriberto Arévalo Ramírez
Diana Santillán-Ruiz
Alexander Briones
Alberto Salazar‐Granara
Date Issued
31 de marzo de 2025
Type
Article
Volume
43
Issue
1
Abstract
Objective: To characterize phenotypic and genotypic profiles, and to determine the prevalence of extended-spectrum betalactamases (ESBLs), AmpC, and carbapenemase resistance genesin gram-negative isolates obtained from COVID-19 patients in five health centers in Peru. Materials and methods: A descriptive and retrospective study was conducted, analyzing 78 bacterial isolates from COVID-19 patients collected during 2020. Bacterial identification and interpretation of antimicrobial susceptibility profiles were performed using the MicroScan® system. Detection of resistance genes blaCTX-M, blaTEM, blaSHV, blaAmpC, blaKPC, blaIMP, and blaNDM was conducted using polymerase chain reaction (PCR). Results: Amongst bacterial isolates analyzed, 49 (62.83%) were Enterobacteriaceae, and 29 (37.17%) were non-fermenting gram-negative bacteria (NFGNB). Escherichia coli was the most prevalent species, with 33 isolates (42.30%). Resistance to antibacterials was observed, including cefotaxime, ciprofloxacin, and aztreonam, while most bacteria remained susceptible to ertapenem, colistin, and tigecycline. PCR analysis revealed that the blaCTX-M gene was the most prevalent, detected in 25.64% of isolates (20/78) and distributed across the five hospitals studied. Conclusions: The findings indicate a high prevalence of bacterial resistance genes in the samples studied, with blaCTX-M and blaTEM being most prevalent in Enterobacteriaceae and blaIMP in non-fermenting bacteria. These findings underscore the need to strengthen AMR surveillance in the context of coinfection in COVID-19 patients.